Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Core outcomes for studies of pregnancy with epilepsy.

Mawer G.

BJOG. 2017 Mar;124(4):668. doi: 10.1111/1471-0528.14432. Epub 2016 Nov 22. No abstract available.

2.

Fine-tuning risk assessment with antiepileptic drug use in pregnancy.

Mawer G, Bromley R, Baker GA, Meador KJ, Clayton-Smith J.

Neurology. 2015 Oct 13;85(15):1354. doi: 10.1212/WNL.0000000000002050. No abstract available.

PMID:
26459942
3.

IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.

Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, García-Fiñana M, Gummery A, Kneen R, Loring DW, Mawer G, Meador KJ, Shallcross R, Clayton-Smith J; Liverpool and Manchester Neurodevelopment Group.

Neurology. 2015 Jan 27;84(4):382-90. doi: 10.1212/WNL.0000000000001182. Epub 2014 Dec 24.

4.

The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs.

Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, García-Fiñana M, Kneen R, Lucas SB, Shallcross R, Baker GA; Liverpool and Manchester Neurodevelopment Group.

J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):637-43. doi: 10.1136/jnnp-2012-304270. Epub 2013 Jan 31.

5.

Early cognitive development in children born to women with epilepsy: a prospective report.

Bromley RL, Mawer G, Love J, Kelly J, Purdy L, McEwan L, Briggs M, Clayton-Smith J, Shi X, Baker GA; Liverpool and Manchester Neurodevelopment Group [LMNDG].

Epilepsia. 2010 Oct;51(10):2058-65. doi: 10.1111/j.1528-1167.2010.02668.x. Erratum in: Epilepsia. 2012 Aug;53(8):1470. Sin, Xin [corrected to Shi, Xin].

6.

Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study.

Mawer G, Briggs M, Baker GA, Bromley R, Coyle H, Eatock J, Kerr L, Kini U, Kuzmyshcheva L, Lucas SB, Wyatt L, Clayton-Smith J; Liverpool & Manchester Neurodevelopment Group.

Seizure. 2010 Mar;19(2):112-9. doi: 10.1016/j.seizure.2009.11.008. Epub 2009 Dec 24.

7.

Autism spectrum disorders following in utero exposure to antiepileptic drugs.

Bromley RL, Mawer G, Clayton-Smith J, Baker GA; Liverpool and Manchester Neurodevelopment Group.

Neurology. 2008 Dec 2;71(23):1923-4. doi: 10.1212/01.wnl.0000339399.64213.1a. No abstract available.

PMID:
19047565
8.

In utero antiepileptic drug exposure: fetal death and malformations.

Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC; NEAD Study Group.

Neurology. 2006 Aug 8;67(3):407-12.

9.

The longer term outcome of children born to mothers with epilepsy.

Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, Mawer G, Nicolaides P, Pickering L, Tunnicliffe L, Chadwick DW.

J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1575-83.

10.
11.
12.
14.

Medical students' errors in pharmacotherapeutics.

Boreham NC, Mawer GE, Foster RW.

Med Educ. 2000 Mar;34(3):188-93.

PMID:
10733704
15.

Factors influencing the incidence of lamotrigine-related skin rash.

Wong IC, Mawer GE, Sander JW.

Ann Pharmacother. 1999 Oct;33(10):1037-42.

PMID:
10534214
16.

The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy.

Wong IC, Chadwick DW, Fenwick PB, Mawer GE, Sander JW.

Epilepsia. 1999 Oct;40(10):1439-45.

17.

Accurate diagnosis of convulsive syncope: role of an implantable subcutaneous ECG monitor.

Zaidi A, Clough P, Mawer G, Fitzpatrick A.

Seizure. 1999 May;8(3):184-6.

19.

Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.

Wong IC, Mawer GE, Sander JW.

BMJ. 1997 Jun 7;314(7095):1693-4. No abstract available.

20.

Interactions involving new antiepileptic drugs.

Mawer GE, Pleuvry BJ.

Pharmacol Ther. 1995;68(2):209-31. Review. Erratum in: Pharmacol Ther 1996;70(3):257.

PMID:
8719968
22.

Fetal phenytoin exposure, hypoplastic nails, and jitteriness.

D'Souza SW, Robertson IG, Donnai D, Mawer G.

Arch Dis Child. 1991 Mar;66(3):320-4.

23.

Sudden death and epilepsy.

Brown SW, Mawer GE, Lawler W, Taylor DC, Shorvon S, Betts TA, Noronha MJ, Richens A, Chadwick D, Besag FM, et al.

Lancet. 1990 Mar 10;335(8689):606-7. No abstract available.

PMID:
1968598
24.

Respiratory and sedative effects of clobazam and clonazepam in volunteers.

Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L.

Br J Clin Pharmacol. 1990 Feb;29(2):169-77.

25.
26.

Seizure frequency and major life events in epilepsy.

Webster A, Mawer GE.

Epilepsia. 1989 Mar-Apr;30(2):162-7.

PMID:
2924742
27.

Phenytoin infusion in severe pre-eclampsia.

Slater RM, Wilcox FL, Smith WD, Donnai P, Patrick J, Richardson T, Mawer GE, D'Souza SW, Anderton JM.

Lancet. 1987 Jun 20;1(8547):1417-21.

PMID:
2884504
28.

The respiratory effects of oral ethyl loflazepate in volunteers.

Fazackerley EJ, Randall NP, Pleuvry BJ, Bradbrook I, Mawer GE.

Br J Clin Pharmacol. 1987 Feb;23(2):183-7.

29.
31.
32.

Estimation of gentamicin clearance and volume of distribution in neonates and young children.

Kelman AW, Thomson AH, Whiting B, Bryson SM, Steedman DA, Mawer GE, Samba-Donga LA.

Br J Clin Pharmacol. 1984 Nov;18(5):685-92.

33.

Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man.

Taylor G, Houston JB, Shaffer J, Mawer G.

Br J Clin Pharmacol. 1983 Mar;15(3):287-93.

34.

Dosage adjustment in renal insufficiency.

Mawer GE.

Br J Clin Pharmacol. 1982 Feb;13(2):145-53. No abstract available.

35.

Serum phenytoin concentration and clinical response in patients with epilepsy.

Gannaway DJ, Mawer GE.

Br J Clin Pharmacol. 1981 Dec;12(6):833-9.

36.

Transfer from multiple to single antiepileptic drug therapy.

Gannaway DJ, Mawer GE.

Lancet. 1981 Jan 24;1(8213):217. No abstract available.

PMID:
6109879
37.

Comparison of medigoxin and digoxin in the control of atrial fibrillation.

Coburn P, Kongola GM, Mawer GE.

Br J Clin Pharmacol. 1979 Jul;8(1):53-8.

38.

Digoxin prescribing: an evaluation of clinical judgment.

Dobbs SM, Nicholson PW, Rodgers EM, Mawer GE, Kenyon WI.

Br Med J. 1978 Sep 2;2(6138):668-9. No abstract available.

39.

Individual variation in daily dosage requirements for phenytoin sodium in patients with epilepsy.

Barot MH, Grant RH, Maheendran KK, Mawer GE, Woodcock BG.

Br J Clin Pharmacol. 1978 Sep;6(3):267-71.

40.

Prediction of digoxin dose requirements.

Dobbs SM, Mawer GE.

Clin Pharmacokinet. 1977 Jul-Aug;2(4):281-91. No abstract available.

PMID:
902448
41.

Factors influencing the therapeutic response to gentamicin treatment in children [proceedings].

Ashurst A, Houston IB, Mawer GE, Sambo-Donga L.

Br J Clin Pharmacol. 1977 Jun;4(3):394P-395P. No abstract available.

42.

Serum digoxin concentrations.

Dobbs SM, Rodgers EM, Mawer GE, Kenyon WI.

Br J Clin Pharmacol. 1976 Aug;3(4):674-6. No abstract available.

43.

Intravenous injection of gentamicin and tobramycin without impairment of hearing.

Dobbs SM, Mawer GE.

J Infect Dis. 1976 Aug;134 Suppl:S114-7.

PMID:
972268
44.

Can digoxin dose requirements be predicted?

Dobbs SM, Mawer GE, Rodgers M, Woodcock BG, Lucas SB.

Br J Clin Pharmacol. 1976 Apr;3(2):231-7.

45.

Computer assisted prescribing of drugs.

Mawer GE.

Clin Pharmacokinet. 1976;1(1):67-78. Review.

PMID:
797493
46.

Experience with a gentamicin nomogram.

Mawer GE, Ahmad R, Dobbs SM, Tooth JA.

Postgrad Med J. 1974 Nov;50 Suppl 7:31-2. No abstract available.

PMID:
4549324
47.

The persistence of adriamycin in man and rat.

Wilkinson PM, Mawer GE.

Br J Clin Pharmacol. 1974 Jun;1(3):241-7.

48.

Phenytoin dose adjustment in epileptic patients.

Mawer GE, Mullen PW, Rodgers M, Robins AJ, Lucas SB.

Br J Clin Pharmacol. 1974 Apr;1(2):163-8.

49.

Prescribing aids for gentamicin.

Mawer GE, Ahmad R, Dobbs SM, McGough JG, Lucas SB, Tooth JA.

Br J Clin Pharmacol. 1974 Feb;1(1):45-50.

50.

An indirect method for the determination of cephaloridine in serum by gas chromatography.

Mullen PW, Mawer GE, Tooth JA.

Res Commun Chem Pathol Pharmacol. 1974 Jan;7(1):85-94. No abstract available.

PMID:
4811462

Supplemental Content

Support Center